drugset / Trial / NCT06474273

TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

NCT06474273

Phase 3 Recruiting 540 enrolled University of Sydney University of Manitoba · collab
RandomizedFactorialQuadruple-blindTreatment

Summary

After a kidney or a simultaneous kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection. One type of rejection is known as Acute T cell mediated rejection (TCMR). This can lead to many problems or even stop the transplant from working. Doctors give strong steroids to treat this problem, but there are no rules for how much steroid to give. Too much steroids can cause problems like heart and bone problems, bad infections, and weight gain. That is why we need to find the right dose of steroids for each person to treat this. TACKLE-IT is a study that will try to find the right steroid dose for treating rejection.

Timeline

Start
2026-03-13
Primary completion
2030-06
Completion
2030-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 150 mg/m2 Intravenous
Subject Methylprednisolone Other / unclassified 250 mg Intravenous
Subject Methylprednisolone Other / unclassified 300 mg/m2 Intravenous
Subject Methylprednisolone Other / unclassified 500 mg Intravenous
Subject Prednisone Other / unclassified 15 mg/m2 Oral
Subject Prednisone Other / unclassified 25 mg Oral
Subject Prednisone Other / unclassified 30 mg/m2 Oral
Subject Prednisone Other / unclassified 50 mg Oral